Document:

Exhibit 101 Non-Employee Director Restricted Stock Plan

		

			Exhibit 10.1

		

		

			 

		

		
			SigmaTron International, Inc.
		

		
			 
		

		
			2021 NON-EMPLOYEE DIRECTOR RESTRICTED STOCK PLAN
		

		
			﻿
		

		
			 
		

		
			SECTION 1
		

		
			﻿
		

		
			PURPOSES OF THE PLAN
		

		
			 
		

		
			The purpose of this 2021 Non-Employee Director Restricted Stock Plan is to promote the success and interests of SigmaTron International, Inc. and enhance the stock ownership of the Directors of the Company by providing a method whereby Non-Employee Directors receive a portion of their annual compensation in restricted shares of the Company’s Common Stock in accordance with this Plan.
		

		
			﻿
		

		
			 
		

		
			SECTION 2
		

		
			﻿
		

		
			DEFINITIONS AND CONSTRUCTION
		

		
			 
		

		
			2.1          Definitions.  As used in the Plan, terms defined parenthetically immediately after their use shall have the respective meanings provided by such definitions, and the terms set forth below shall have the following meanings (in either case, such terms shall apply equally to both the singular and plural forms of the terms defined):
		

		
			 
		

			
	
			
				 (a)
			“Award” means any Common Stock awarded under the Plan.

		
			﻿
		

			
	
			
				 (b)
			“Award Agreement” means the agreement, certificate or other instrument evidencing the grant of any Award under the Plan.

		
			﻿
		

			
	
			
				 (c)
			“Awarded Stock” means the Common Stock awarded to a Grantee pursuant to the Plan which is subject to any forfeiture and/or restrictions on transferability in accordance with Section 6 of the Plan.

		
			﻿
		

			
	
			
				 (d)
			“Board” means the Board of Directors of the Company.

		
			﻿
		

		
			(e) “Cause” means: (i) a felony conviction of a Grantee or the failure of a Grantee to contest prosecution for a felony; or (ii) a Grantee’s willful misconduct or dishonesty, any of which is determined by the Board to be directly and materially harmful to the business or reputation of the Company.  
		

		
			﻿
		

			
	
			
				 (e)
			“Code” means the Internal Revenue Code of 1986, as amended from time to time, and any successor thereto.

		
			﻿
		

			
	
			
				 (f)
			“Committee” means the Compensation Committee of the Board.

		
			﻿
		

			
	
			
				 (g)
			“Common Stock” means the common stock of the Company.

		
			﻿
		

			
	
			
				 (h)
			“Company” means SigmaTron International, Inc., a Delaware corporation.

		
			﻿
		

			
	
			
				 (i)
			“Director” means a director serving on the Board.

		
			﻿
		

			
	
			
				 (j)
			“Disability” means permanent and total disability as determined under procedures established by the Board for purposes of the Plan.

		
			﻿
		

			
	
			
				 (k)
			“Exchange Act” means the Securities Exchange Act of 1934, as amended from time to time, and any successor thereto.

		
			﻿
		

			
	
			
				 (l)
			“Fair Market Value” means as of any specified date, the closing price of the Common Stock on NASDAQ (or, if the Common Stock is not then listed on such exchange, such other national securities exchange or other market on which the Common Stock is then listed or admitted to trading, as the case may be) on that date, or if no prices are reported on that date, on the last preceding date on which such prices of the Common Stock are reported.

		

		

		 

		

			 

		

		

			Page 1 of 5

		

 

		
		

			
	
			
				 (m)
			“Grant Date” means the date on which the Committee granted an Award to a Grantee.

		
			﻿
		

			
	
			
				 (n)
			“Grantee” means a Non-Employee Director who has been granted an Award, or the personal representative, heir or legatee of the Grantee who has rights to Awarded Stock.

		
			﻿
		

			
	
			
				 (o)
			“Non-Employee Director” means a member of the Board who is not an employee of the Company or any Subsidiary of the Corporation.

		
			﻿
		

			
	
			
				 (p)
			“Plan” means this 2021 Non-Employee Director Restricted Stock Plan, as the same may be amended from time to time.

		
			﻿
		

			
	
			
				 (q)
			“Restriction Period” means the period during which shares of Awarded Stock are subject to forfeiture or restrictions on transfer (if applicable) as described in Section 6 of the Plan and any applicable Award Agreement.

		
			﻿
		

			
	
			
				 (r)
			“Retirement” means a Non-Employee Director’s voluntary retirement from the Board.

		
			﻿
		

			
	
			
				 (s)
			“Securities Act” means the Securities Act of 1933, as amended from time to time, and any successor thereto.

		
			 
		

		
			2.2          Gender and Number.  Except where otherwise indicated by the context, reference to the masculine gender shall include the feminine gender, the plural shall include the singular and the singular shall include the plural.
		

		
			 
		

		
			2.3          Severability.  In the event any provision of the Plan shall be held illegal or invalid for any reason, the illegality or invalidity shall not affect the remaining parts of the Plan, and the Plan shall be construed and enforced as if the illegal or invalid provision had not been included.
		

		
			 
		

		
			﻿
		

		
			SECTION 3
		

		
			﻿
		

		
			SHARES SUBJECT TO THE PLAN
		

		
			 
		

		
			3.1          Shares Available.  The Common Stock to be offered under the Plan may be authorized, but unissued Common Stock or Common Stock held in treasury.  The aggregate number of shares of Common Stock subject to Awards under the Plan shall not exceed 75,000 shares, subject to the adjustments provided in Section 7.
		

		
			 
		

		
			3.2          Canceled, Terminated or Forfeited Awards.  Any shares of Common Stock subject to any portion of an Award which, in any such case and for any reason, expires, or is canceled, terminated or otherwise forfeited, without the recipient having received any benefits of ownership (as such phrase is construed by the Securities and Exchange Commission or its staff), shall again be available for distribution in connection with Awards under the Plan.
		

		
			﻿
		

		
			﻿
		

		
			SECTION 4
		

		
			﻿
		

		
			ADMINISTRATION
		

		
			﻿
		

		
			4.1          General.  The Plan shall be administered by the Committee.  Subject to the express provisions of the Plan, the Committee shall have all of the powers to construe and interpret the Plan and to determine all questions that shall arise thereunder.  Without limiting the foregoing, the Committee shall have authority to interpret the Plan, to prescribe, amend and rescind rules and regulations relating to it, to determine the terms and provisions of the Awards and Agreements (which shall comply with and be subject to the terms and conditions of the Plan) and to make all other determinations necessary or advisable for the administration of the Plan.  Except to the extent otherwise provided by law, the Committee’s determination of the matters referred to in this Section 4.1 shall be conclusive, final and binding on the Company and the Grantees, their heirs and/or beneficiaries.
		

		
			 
		

		
			4.2          Section 16 Compliance.  It is the intention of the Company that the Plan and the administration of the Plan comply in all respects with Section 16(b) of the Exchange Act and the rules and regulations promulgated thereunder.  If any Plan provision, or any aspect of the administration of the Plan, is found not to be in compliance with Section 16(b) of the Exchange Act, the provision or administration shall be deemed null and void, and in all events the Plan shall be construed in favor of its meeting the requirements of Rule 16b-3 promulgated under the Exchange Act.
		

		
			 
		

		

		

		 

		

			 

		

		

			Page 2 of 5

		

 

		
		

		
			﻿
		

		
			SECTION 5  
		

		
			﻿
		

		
			ELIGIBILITY AND PARTICIPATION
		

		
			 
		

		
			Participation in the Plan shall be limited to Non-Employee Directors.  A director who is an employee of the Company and who retires or resigned from employment with the Company and/or any of its subsidiaries, but remains a director of the Company, shall become eligible to participate in the Plan at the time of such termination of employment.  Subject to the terms of the Plan, the Committee shall determine the amount of, and terms of, all Awards to eligible Non-Employee Directors.
		

		
			 
		

		
			 
		

		
			SECTION 6 
		

		
			﻿
		

		
			AWARD TERMS
		

		
			 
		

		
			6.1          Awards and Certificates.
		

		
			 
		

			
	
			
				 (a)
			Awarded Stock shall be evidenced in such manner as the Committee may deem appropriate, including book-entry registration or issuance of one or more stock certificates.  Any certificate issued in respect of any Award shall be registered in the name of the Grantee and shall bear an appropriate legend referring to the terms, conditions and restrictions applicable to such Award, substantially in the following form:

		
			﻿
		

		
			“THE TRANSFERABILITY OF THIS CERTIFICATE AND THE SHARES OF STOCK REPRESENTED HEREBY ARE SUBJECT TO THE TERMS AND CONDITIONS (INCLUDING FORFEITURE) OF THE 2021 NON-EMPLOYEE DIRECTOR RESTRICTED STOCK PLAN OF SIGMATRON INTERNATIONAL, INC. AND AN AWARD AGREEMENT.  COPIES OF SUCH PLAN AND AGREEMENT ARE ON FILE AT THE OFFICES OF SIGMATRON INTERNATIONAL, INC.” 
		

		
			﻿
		

			
	
			
				 (b)
			The Committee may require that the certificates evidencing such shares be held in custody by the Company until the restrictions thereon shall have lapsed and that, as a condition of any Award, the Grantee shall have delivered a stock power, endorsed in blank, relating to the Common Stock covered by such Award.

		
			﻿
		

			
	
			
				 (c)
			Upon the end of the Restriction Period and provided that the Awarded Stock has not been forfeited, the Company shall, upon the Grantee’s request or upon its own initiative, issue or have issued new certificates without the legend described in Section 6.1(a), in exchange for those certificates previously issued.

		
			﻿
		

		
			6.2          Terms and Conditions.   Awarded Stock shall be subject to the following terms and conditions:
		

		
			 
		

			
	
			
				 (a)
			Vesting.  All Awarded Stock shall be vested on the six-month anniversary of the Grant Date.

		
			﻿
		

			
	
			
				 (b)
			Restrictions on Transfer.  Subject to the provisions of the Plan and the Award Agreement referred to in Section 6.2(g), and until the expiration of the six-month anniversary of the Grant Date (“Restriction Period”), the Grantee shall not be permitted to sell, assign, transfer, pledge or otherwise encumber Awarded Stock; however, the Grantee shall have the right to receive dividends with respect to the Awarded Stock and to vote the shares of the Awarded Stock prior to the expiration of the Restriction Period.

		
			﻿
		

			
	
			
				 (c)
			Rights with Respect to Awarded Stock.  Except as provided in Sections 6.2(b) and this 6.2(c) and the Award Agreement, the Grantee shall have, with respect to the Awarded Stock, all of the rights of a holder of Common Stock including the right to vote the Awarded Stock and, if granted by the Board, the right to receive any dividends.

		
			﻿
		

			
	
			
				 (d)
			Forfeiture of Unvested Awarded Stock.  Except to the extent otherwise provided in the applicable Award Agreement and Sections 6.2(a) and 6.2(f), if a Grantee ceases to be a Non-Employee Director of the Company for any reason other than death, Disability or Retirement, or Cause, all unvested Awarded Stock shall be forfeited as of the date the Grantee ceases to be a Non-Employee Director.

		
			﻿
		

			
	
			
				 (e)
			If a Grantee ceases to be a Director of the Company because of removal for Cause, all unvested Awarded Stock shall be forfeited as of the date the Grantee ceases to be a Director.

		

		

		 

		

			 

		

		

			Page 3 of 5

		

 

		
		

		
			﻿
		

			
	
			
				 (f)
			In the event of a Grantee’s death, Disability or Retirement while a Director of the Company, all unvested Awarded Stock shall become fully vested and all restrictions (other than restrictions on transferability in the absence of registration of the Awarded Stock under the Securities Act or the availability of an exemption therefrom), shall end as of the date of such death, Disability or Retirement.

		
			﻿
		

			
	
			
				 (g)
			Each Award shall be confirmed by, and be subject to, the terms of an Award Agreement.

		
			﻿
		

			
	
			
				 (h)
			The Committee may at any time accelerate the vesting of all or any portion of any Award or provide for the lapsing of any conditions or restrictions on any outstanding Award, or portion thereof.

		
			﻿
		

		
			﻿
		

		
			SECTION 7
		

		
			﻿
		

		
			ADJUSTMENTS UPON CHANGE IN CAPITALIZATION
		

		
			 
		

		
			Notwithstanding the limitations set forth in Section 3, in the event of a merger, reorganization, consolidation, recapitalization, reclassification, split-up, spin-off, separation, liquidation, stock dividend, stock split, reverse stock split, property dividend, share repurchase, share combination, share exchange, issuance of warrants, rights or debentures or other change in corporate structure of the Company affecting the Common Stock, the Committee shall make such substitution or adjustments in the aggregate number and kind of shares reserved for issuance under the Plan, in the number of shares subject to outstanding Awards, and/or such other equitable substitution or adjustments as it may determine to be appropriate in its sole discretion; provided, however, that the number of shares subject to any Award shall always be a whole number.
		

		
			﻿
		

		
			﻿
		

		
			SECTION 8
		

		
			﻿
		

		
			TERMINATION AND AMENDMENT
		

		
			 
		

		
			The Committee shall have the right and power at any time and from time to time to amend or alter the Plan, in whole or in part, and at any time to terminate the Plan, provided however, that an amendment to the Plan may be conditioned upon the approval of the stockholders of the Company if and to the extent the Committee determines that stockholder approval is necessary, appropriate, or required by law or agreement.    Notwithstanding the foregoing, any termination, amendment, or modification of the Plan shall not, in any material way, adversely affect any Awarded Stock previously granted under the Plan without the written consent of the affected Grantee.
		

		
			﻿
		

		
			 
		

		
			SECTION 9
		

		
			﻿
		

		
			NO WITHHOLDING
		

		
			 
		

		
			Each Grantee shall be responsible for the payment of any taxes required by law to be paid in respect of Awards under the Plan and the Company shall make no withholding with respect to any Award.
		

		
			 
		

		
			﻿
		

		
			SECTION 10
		

		
			﻿
		

		
			NO RIGHT TO RE-ELECTION
		

		
			 
		

		
			Nothing in the Plan or in any Award granted pursuant to the Plan or any action taken under the Plan shall confer on any individual any right to continue as a Non-Employee Director or director of the Company or to be re-nominated by the Board or re-elected by the stockholders of the Company.
		

		
			 
		

		
			﻿
		

		
			SECTION 11
		

		
			﻿
		

		
			TERM OF THE PLAN
		

		
			 
		

		
			The Plan shall become effective only upon approval by the stockholders of the Company and, unless earlier terminated in accordance with the provisions of the Plan, shall remain in effect for a term of ten (10) years from the date of such stockholder approval. 
		

		
			﻿
		

		

		

		 

		

			 

		

		

			Page 4 of 5

		

 

		﻿
		

		
			SECTION 12
		

		
			﻿
		

		
			GOVERNING LAW
		

		
			 
		

		
			To the extent that state laws shall not have been preempted by any laws of the United States, the Plan shall be construed, regulated, interpreted and administered according to the laws of the State of Delaware without regard to its conflict of laws rules.
		

		
			﻿
		

		 

		

			 

		

		

			Page 5 of 5Document

August 11, 2021
PRIVATE AND CONFIDENTIAL
Ramona Seabaugh    

Dear Ramona,

Re: Offer of Employment
We at MedAvail Technologies (US), Inc. (“MedAvail” or the “Company”) believe that we are able to provide you with exciting and challenging career opportunities as part of our team.
MedAvail is pleased to extend to you an offer of employment on the terms and conditions outlined below. 
1.Title.  You will be employed as Chief Financial Officer, MedAvail. You will be reporting directly to the Chief Executive Officer of MedAvail.  
2.Commencement Date. Your employment with us will begin on or about Monday, September 20, 2021 (“Commencement Date”). 
3.Duties and Position.   You agree to devote your whole working time to the performance of your duties and to perform your duties and responsibilities, as assigned to you from time to time by the Company, faithfully and to the best of your ability. Your duties are subject to change to meet Company needs. You agree to act in the best interests of the Company at all times.  While you are employed, you agree that you will not be employed by or obtain an ownership interest in any other entity or person who is a competitor of the Company, or where you may be placed in a position of conflict with the Company.  You will be able to join one (1) non-competitive for-profit Board no sooner than after one 1) year of employment with the Company.
4.Base Salary. You will be paid an annual base salary of $325,000.00 USD (gross) subject to required statutory and other deductions which are hereby authorized by you. Your salary will be paid on a bi-weekly basis. With your authorization, this payment will be made directly into a bank account designated by you.  
5.Sign on Bonus.  You will be paid a signing bonus of $70,000 USD (gross) within twenty (20) business days following your Commencement Date.  This signing bonus will be subject to required statutory and other deductions which are hereby authorized by you.  

With your authorization, this payment will be made directly into a bank account designated by you.
6.Vacation. You will be entitled to five (5) weeks’ vacation for every twelve months of employment. Vacation is accrued each pay period and balances available for your review in our HRIS system.
7.Benefits.  You will be eligible to participate in our group health benefit plans the first day of the month immediately following the first day of employment.  In accordance with their terms, the details of which will be available upon the commencement of your employment with the Company. The group benefit plans may be amended at the Company’s sole discretion from time to time, and so long as the modified terms apply generally to employees, you agree that any such modification will not constitute constructive dismissal.
8.Short Term Incentive Plan. The Company’s Short Term Incentive Plan (“STIP”) is a discretionary bonus plan designed to support the overall compensation structure as a component of total compensation. You will be eligible for the opportunity to earn up to forty (40) percent of your base salary as an STIP bonus. The MedAvail Board of Directors will determine the corporate objectives and approve your departmental and individual objectives for each calendar year. In generally, fifty (50) percent of any STIP award is based on the achievement of the Company’s corporate objectives and the remaining fifty (50) percent is based on achievement of your departmental and individual objectives. The amount of any STIP bonus is determined at the discretion of the MedAvail Board of Directors and is not guaranteed to be paid in any given calendar year, or at all.  The MedAvail Board of Directors will have sole discretion in determining whether any STIP award will be provided by way of cash or options granted pursuant to the Employee Stock Option Plan of MedAvail, Inc.  You must be an active employee working at MedAvail on the date STIP bonuses are paid and not have given notice of resignation for a future date, in order for you to be eligible to receive any such STIP that you would otherwise be entitled to.
9.Equity Awards. Promptly following the Commencement Date, the Company will recommend to its Board of Directors (the “Board”) that you be provided with initial equity awards valued at $650,000.  The initial equity awards will be equally divided 50% in the form of an option (the “Option”) and 50% in the form of a restricted stock unit award (“RSU Award”).  The number of shares subject to the Option will be calculated based on a Black-Scholes value with an exercise price equal to the closing price of the Company’s common stock on the date of grant. The RSU Award will be calculated based on the closing price of the Company’s common stock on the date of grant. The Option and the RSU Award will be issued pursuant to the MedAvail Holdings, Inc. 2020 Equity Incentive Plan (the “ESOP Plan”) and will be subject to the approval of the Board. Subject to the Stock Option Agreement, Restricted Stock Unit Award Agreement and 

detailed provisions of the ESOP Plan, your Option will vest over 4 years from the date of grant, at a rate of 1/48th per month and your RSU Award will vest over 3 years with a cliff vest every 12 months.   Vesting is subject to you continuing to be a Service Provider (as defined in the ESOP Plan) through each vesting date.  You will be required to sign both the definitive Stock Option Agreement & Restricted Stock Unit Award Agreement documenting your Option and RSU Award in which you affirm that your rights with respect to both will be subject to the applicable terms in the ESOP Plan and your agreements. The Board of Directors may from time to time alter the terms and conditions of the ESOP Plan on a go forward basis, without notice to you.  
10.Severance.  You will be eligible to enter into a Change in Control and Severance Agreement (the “Severance Agreement”) applicable to you based on your position with the Company.  The Severance Agreement will specify the severance payments and benefits you would be eligible to receive in connection with certain terminations of your employment with the Company.  These protections will supersede all other severance payments and benefits you would become eligible for in the future, under any plan, program or policy that the Company may have in effect from time to time.
11.Expenses. You shall be entitled to be reimbursed for all reasonable expenses duly and properly incurred for the performance of your duties in accordance with Company policies in effect from time to time. 
12.Hours of Work. In the execution of your duties, you will be expected to work not less than 40 hours per week, and in the evenings and on weekends where required. Your position is classified as exempt and does not qualify for overtime pay.  You will be expected to travel throughout the US and to the Canadian headquarters of the Company from time to time.
13.Policies.  You agree to abide by the rules, regulations, personnel practices, directives, programs and policies (the “Policies”) of the Company as issued and in effect at any time during your employment. On an annual basis, or otherwise as may be reasonably required by the Company, you shall be required to certify your commitment to comply with the Policies, which are subject to amendment by the Company at any time and from time to time. 
14.Conditions. This offer and your continued employment is conditional upon the following:
(a)You shall provide documentation permitted on the Form I-9 establishing that you are legally authorized to work in the United States, and you agree to indemnify the Company and its subsidiaries from any claims, damages, costs or expenses caused by the breach of this representation

(b)You shall provide a copy of a valid US passport; 
(c)You shall submit to a credit check and/or security search and/or reference check to be conducted at the Company’s expense.  Your employment with the Company is conditional upon the Company being satisfied with the results of such searches, in its sole discretion;
(d)You shall submit (at the request of the Company) to a drug screen at the expense of and at a laboratory designated by the Company.  This offer of employment is contingent upon the Company being satisfied with the results of your drug screen, in the Company’s sole discretion; and
(e)You confirm that you have no obligations to third parties that would prevent you from performing your duties and responsibilities set out herein.
15.Confidentiality.  As a condition of your continued employment, you are also required to sign and comply with an At Will Employment, Confidential Information, Invention Assignment and Arbitration Agreement in the Company’s standard form (the “Confidentiality Agreement”) which requires, among other provisions, the assignment of patent rights to any invention made during your employment at the Company, and non-disclosure of Company proprietary information. In the event of any dispute or claim relating to or arising out of our employment relationship, you and the Company agree that (i) any and all disputes between you and the Company shall be fully and finally resolved by binding arbitration, (ii) you are waiving any and all rights to a jury trial but all court remedies will be available in arbitration, (iii) all disputes shall be resolved by a neutral arbitrator who shall issue a written opinion, (iv) the arbitration shall provide for adequate discovery, and (v) the Company shall pay all the arbitration fees, except an amount equal to the filing fees you would have paid had you filed a complaint in a court of law. Please note that we must receive your signed Confidentiality Agreement before the Transition Date.
16.Termination of Employment. If you choose to accept this offer of Employment, your employment by the Company will be at-will, which means that either you or the Company may terminate your employment at any time and for any reason with or without notice. This offer letter does not constitute a contract or guarantee of continued employment, and the Company retains the right to modify, amend, or cancel the benefits and payments summarized in this letter at any time and without prior notice. 
Upon termination of employment, by the next regularly scheduled payday you will be paid your wages earned through your date of termination as well as payment for all accrued but unused vacation days.

You acknowledge that, if you decide to terminate your employment with the Company, you will give the Company a minimum of two (2) weeks’ notice and during that period of notice, cooperate fully in the transitioning of your role.  
17.Independent Legal Advice. You acknowledge that you have read and understood this Agreement and have been advised by us to seek independent legal advice and have been given a reasonable opportunity to seek and obtain such advice before signing the agreement.
18.Severability. If any provision contained in this Agreement (or part thereof) is determined to be unenforceable in whole or in part by a Court of competent jurisdiction, such invalid provision (or part thereof) shall be severed and the remaining terms will remain in full force and effect.  
19.Entire Agreement. This Agreement constitutes the entire agreement between you and the Company.  Any representations, oral or written, that are not expressly included in this Agreement are superseded and of no force or effect.  
20.Counterparts.  This Agreement may be executed simultaneously in counterparts (including by means of electronically transmitted reproductions of signature pages), each of which shall be deemed an original, but both of which together constitute one and the same instrument.
21.Governing Law. The law of the state of Arizona governs the interpretation of this Agreement without regard to any choice of law or conflict of laws rules, provisions or principles (whether of the State of Arizona or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Arizona.
We look forward to you joining MedAvail. If you choose to voluntarily accept this offer, please return an executed copy of this letter to us. 
Yours truly,
MedAvail Technologies (US) Inc.
Per: /s/ Ed Kilroy

			
	Ed Kilroy – Chief Executive Officer

ACCEPTANCE
I have had the opportunity to review this offer of employment, understand its terms, and accept the terms offered above.  I confirm that there are no terms which have been promised to me other than those described above. I acknowledge that I am able to consult with legal counsel, at my own cost, and that I am voluntarily accepting this offer.  
												
	/s/ Ramona Seabaugh		
	
	Ramona Seabaugh			Date: August 12, 2021

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}]]